Subcutaneous anti-PD-L1 monoclonal antibody Envafolimab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment for advanced biliary tract cancer in Chinese patients: A randomized, open-label, multicenter, registrational phase III trial

oxaliplatin - Generic mfg.

Enweida (envafolimab) - 3DMed, Ascletis

gemcitabine - Generic mfg.

https://cslide.ctimeetingtech.com/esmo2026/attendee/confcal_1/print/presentation/7281

Shukui Qin; Weijia Fang; Haitao Zhao; Xianglin Yuan; ShanZhi Gu; Wei Li; Jie Ma; Kangsheng Gu; Zhenggang Ren; Yueyin Pan; Tao Zhang; Lan Qin; Yajin Chen; Zishu Wang; Xiufeng Liu; Yan Wang; Yue He; Houjie Liang

Jul 17, 2026